Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study is for patients with advanced cancer that has failed treatment with conventional
therapy or for which no standard treatment exists. The purpose of this study is to determine
the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere)
and liposomal doxorubicin (also called Doxil), when given together and to determine the side
effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease
the size of several different tumors. Taxotere is approved by the Food and Drug
Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for
the treatment of ovarian cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of Southern California
Collaborator:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA